VTYX
Ventyx Biosciences, Inc.Price
Daily candles with volume.
Signal stack
Where each data set points today.
- InsidersNO TRADES
No open-market buys or sells since Mar 4. Recent filings are awards, exercises and tax withholding.
- InstitutionsBEARISH
Q1 2026: 0 added (0 new), 4 trimmed or exited.
- EstimatesFALLING
Current-quarter EPS estimate −$0.364 → −$0.394 over 90 days. 1 up, 0 down in 30 days.
Who's buying
13F· Q1 2026| Fund | Move | Value |
|---|---|---|
| MORGAN STANLEY | EXIT | $0.00 |
| Connor, Clark & Lunn Investment Management Ltd. | EXIT | $0.00 |
| BAKER BROS. ADVISORS LP | EXIT | $0.00 |
| BlackRock, Inc. | EXIT | $0.00 |
| MORGAN STANLEY | DOUBLED | $38.8M |
| BlackRock, Inc. | DOUBLED | $28.4M |
| BAKER BROS. ADVISORS LP | DOUBLED | $21.2M |
| D. E. Shaw & Co., Inc. | DOUBLED | $15.0M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
last action Jan 2026| Date | Firm | Rating |
|---|---|---|
| Jan 8, 2026 | Oppenheimer DOWNGRADE | Perform |
| Jan 8, 2026 | Wells Fargo DOWNGRADE | Equal-Weight |
| Jan 8, 2026 | HC Wainwright & Co. DOWNGRADE | Neutral |
| Jan 8, 2026 | UBS DOWNGRADE | Neutral |
| Jan 8, 2026 | LifeSci Capital DOWNGRADE | Market Perform |
| Jan 8, 2026 | Canaccord Genuity DOWNGRADE | Hold |
Insider ledger
Form 4| Date | Insider | Type | Value |
|---|---|---|---|
| Mar 4, 2026 | White William Richard Director | TO ISSUER | 119,120 sh |
| Mar 4, 2026 | Nuss John CHIEF SCIENTIFIC OFFICER | TO ISSUER | 415,104 sh |
| Mar 4, 2026 | Mohan Raju CEO AND PRESIDENT | TO ISSUER | 23,688 sh |
| Mar 4, 2026 | Gonzales Roy Senior VP, Finance | TO ISSUER | 109,200 sh |
| Mar 4, 2026 | Gonzales Roy Senior VP, Finance | TO ISSUER | 12,500 sh |
| Mar 4, 2026 | Nuss John CHIEF SCIENTIFIC OFFICER | TO ISSUER | 192,778 sh |
| Mar 4, 2026 | Mohan Raju CEO AND PRESIDENT | TO ISSUER | 700,000 sh |
| Mar 4, 2026 | Mohan Raju CEO AND PRESIDENT | TO ISSUER | 473,750 sh |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Next Q | -$0.40 | -$0.51–-$0.28 | -3.9% | $0.00 |
| Next FY | -$1.57 | -$2.08–-$1.23 | +3.9% | $0.00 |
| Current Q | -$0.39 | -$0.49–-$0.29 | -8.8% | $0.00 |
| Current FY | -$1.48 | -$1.57–-$1.37 | -2.4% | $0.00 |
SecBot reports
3 filings · 0 bullish · 2 bearish · 1 neutral- BEARISH INST-CLUSTERJun 11, 2026
A bearish institutional cluster has formed in Ventyx Biosciences (VTYX) for Q3 2025, with 4…
The cluster is uniformly passive, reducing signal value — likely rebalancing or risk-limit trimming rather than a fundamental downgrade. However, the 4:1 seller ratio and the absence of any active…
- BEARISH 15-12GMar 16, 2026
Ventyx Biosciences, Inc. (VTYX) has filed Form 15-12G to terminate the registration of its Common…
Traders should expect delisting from Nasdaq and a move to OTC or complete deregistration. The presence of Eli Lilly's address and only one holder of record strongly suggests the company has been…
- NEUTRAL EFFECTMar 9, 2026
Ventyx Biosciences, Inc. has two Form EFFECT filings with effectiveness dates of March 6, 2026…
Traders should monitor for upcoming prospectus supplements or pricing announcements that will disclose the size, price, and use of proceeds for the offerings. The dual effectiveness suggests Ventyx…
All VTYX filing & press-release reports (3)
- INST-CLUSTER reportJun 11, 2026
- 15-12G reportMar 16, 2026
- EFFECT reportMar 9, 2026